Point-of-care screening test for early cervical cancer detection

用于早期宫颈癌检测的护理点筛查测试

基本信息

  • 批准号:
    10650144
  • 负责人:
  • 金额:
    $ 40.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-22 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

SUMMARY ABSTRACT Although cervical cancer is an easily curable disease if detected early, it continues to claim the lives of hundreds of thousands of women worldwide. Healthcare disparities have resulted in cervical cancer incidence and mortality that are five times higher in low and middle income countries (LMICs) than in high-income countries. In the United States, cervical cancer mortality rates are twice as high among rural women than their urban counterparts. The wide disparity in cervical cancer incidence rates and deaths is attributed to both higher HPV infection rates and a lack of accessible screening and treatment of pre-invasive cervical lesions. The current standard of care in the US, a cytology-based Pap smear, requires resource intensive laboratory and clinical specialists with a long turnaround time from sample collection to result. Alternatives, such as visual inspection with acetic acid and emerging HPV-targeted tests, have poor specificity for cervical cancer, leading to overtreatment that can cause complications including infertility and pre-term births and that further the burden on limited healthcare resources. This proposal aims to create an integrated point-of-care screening test that can be used by healthcare providers in under-resourced settings to obtain relevant clinical insights, including cervical cancer risk stratification, and enable same-visit treatment of high risk cervical lesions. Building on our preliminary development of a highly sensitive paper-based immunoassay to test for the key cervical cancer biomarker, valosin containing protein (VCP), the objective of this proposal is to combine VCP detection with three other known cervical cancer protein biomarkers, in a sensitive and specific single-step point- of-care assay. Specific milestones include: 1) Integrating and optimizing multiplex detection of cervical cancer biomarkers into a simple paper-based sample-to-answer device. 2) Evaluating the operational and performance metrics of the test in retrospective cervical swab samples. The outcome of this proposal will be a highly characterized point-of-care test with high sensitivity (95%) and specificity (90%) to detect high-risk cervical intraepithelial neoplasia and invasive cervical cancer within 40 minutes. This affordable solution for cervical cancer screening and control programs will be applicable in LMICs and will provide highly sensitive monitoring of cervical intraepithelial neoplasia in the US, where it will be especially impactful in high-risk populations that are currently underserved by existing screening programs.
摘要 虽然子宫颈癌是一种容易治愈的疾病,如果早期发现,它继续夺去生命, 全世界成千上万的女性。医疗保健差异导致宫颈癌发病率 低收入和中等收入国家的死亡率是高收入国家的五倍。 在美国,农村妇女的宫颈癌死亡率是城市妇女的两倍。 同行宫颈癌发病率和死亡率的巨大差异归因于较高的HPV 感染率以及缺乏对浸润前宫颈病变的筛查和治疗。 美国目前的护理标准是基于细胞学的巴氏涂片检查,需要资源密集型实验室 和临床专家,从样本采集到结果的周转时间很长。替代方案,如视觉 醋酸检查和新出现的HPV靶向检测对宫颈癌的特异性较差, 过度治疗可能导致并发症,包括不孕症和早产, 有限的医疗资源。该提案旨在创建一种综合的即时筛查测试, 供资源不足环境中的医疗保健提供者使用,以获得相关的临床见解,包括宫颈 癌症风险分层,并实现高危宫颈病变的同一次就诊治疗。 基于我们初步开发的一种高灵敏度的纸基免疫检测方法, 宫颈癌生物标志物,含Valosin蛋白(VCP),本提案的目的是将联合收割机VCP 检测与其他三个已知的宫颈癌蛋白质生物标志物,在一个敏感和特定的单步点- 护理测定。 具体里程碑包括: 1)整合和优化宫颈癌生物标志物的多重检测到一个简单的纸基 采样-应答装置 2)在回顾性宫颈拭子样本中评价检测的操作和性能指标。 该提案的结果将是一个高度特征化的床旁检测,具有高灵敏度(95%), 特异性(90%)检测高危宫颈上皮内瘤变和浸润性宫颈癌在40 分钟这种负担得起的宫颈癌筛查和控制方案将适用于中低收入国家 并将在美国提供高度敏感的宫颈上皮内瘤变监测, 特别是对目前现有筛查项目服务不足的高危人群有影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jacqueline Linnes其他文献

Jacqueline Linnes的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jacqueline Linnes', 18)}}的其他基金

Point-of-care screening test for early cervical cancer detection
用于早期宫颈癌检测的护理点筛查测试
  • 批准号:
    10443827
  • 财政年份:
    2020
  • 资助金额:
    $ 40.54万
  • 项目类别:
Point-of-care screening test for early cervical cancer detection
用于早期宫颈癌检测的护理点筛查测试
  • 批准号:
    10267737
  • 财政年份:
    2020
  • 资助金额:
    $ 40.54万
  • 项目类别:
Pont-of-use Acute HIV Infection Diagnostic for Substance Using Populations
针对药物使用人群的使用点急性 HIV 感染诊断
  • 批准号:
    10056083
  • 财政年份:
    2020
  • 资助金额:
    $ 40.54万
  • 项目类别:
Pont-of-use Acute HIV Infection Diagnostic for Substance Using Populations
针对药物使用人群的使用点急性 HIV 感染诊断
  • 批准号:
    10794830
  • 财政年份:
    2020
  • 资助金额:
    $ 40.54万
  • 项目类别:
Smartphone-based diagnostic for HIV self-testing
基于智能手机的 HIV 自检诊断
  • 批准号:
    10455110
  • 财政年份:
    2018
  • 资助金额:
    $ 40.54万
  • 项目类别:
Smartphone-based diagnostic for HIV self-testing
基于智能手机的 HIV 自检诊断
  • 批准号:
    10423656
  • 财政年份:
    2018
  • 资助金额:
    $ 40.54万
  • 项目类别:
Smartphone-based diagnostic for HIV self-testing
基于智能手机的 HIV 自检诊断
  • 批准号:
    9756313
  • 财政年份:
    2018
  • 资助金额:
    $ 40.54万
  • 项目类别:
A Rapid Instrument Free Molecular Diagnostic for B. Pertussis
百日咳博德特氏菌的快速无仪器分子诊断
  • 批准号:
    8718586
  • 财政年份:
    2014
  • 资助金额:
    $ 40.54万
  • 项目类别:
A Rapid Instrument Free Molecular Diagnostic for B. Pertussis
百日咳博德特氏菌的快速无仪器分子诊断
  • 批准号:
    8802766
  • 财政年份:
    2014
  • 资助金额:
    $ 40.54万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 40.54万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 40.54万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 40.54万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.54万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 40.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 40.54万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 40.54万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 40.54万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 40.54万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 40.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了